Boulder biopharma firm, CEO and former exec settle with SEC for $20.8 million

The SEC had alleged the firm misled its investors about the effectiveness of the company ’s cancer drug.

Source: bizjournals.com Health Care:Biotechnology headlines - September 19, 2018 Category: Biotechnology Authors: Monica Vendituoli Source Type: news